摘要
目的:研究增生性糖尿病视网膜病变(PDR)患者进行视网膜全光凝(PRP)治疗前后血浆中血管内皮生长因子(VEGF)、内皮素-1(ET-1)和一氧化氮(NO)含量的变化。方法:对40例患有PDR但未经过PRP治疗的的患者进行前瞻性研究,其中女23例,男17例,平均年龄48.5±12.2岁,同时选取30例年龄性别相匹配的健康人群作为健康对照组。分别在激光治疗前(作为基线值)和完成最后一次光凝治疗后3mo抽取患者的血样,采用酶联免疫吸附法(ELISA)检测血浆中VEGF,ET-1和NO的含量。分别将激光治疗前患者血浆中VEGF,ET-1和NO含量基线值分别和健康对照组,以及经视网膜全光凝治疗后3mo的检测值进行比较分析。结果:患有PDR的患者血浆中VEGF(375±89ng/L),ET-1(20±5ng/L)和NO(135±53μmol/L)的含量均比健康对照组高(P<0.01),经过视网膜全光凝治疗3mo后,上述各检测指标分别下降至VEGF(179±66ng/L)、ET-1(11±5ng/L)和NO(91±49μmol/L),但仍比健康对照组高。结论:患有PDR的患者血浆中含有较高的VEGF、ET-1和NO,经过视网膜全光凝治疗后显著下降。
AIM- To study plasma levels of vascular endothelial growth factor （VEGF）, endothelin-1 （ ET-1 ） and nitric oxide （NO） in patients with proliferative diabetic retinopathy （PDR） before and after pan-retinal photocoagulation （PRP）. METHODS： In this prospective study, forty patients （23 females and 17 males, mean age 48.5 ± 12.2） with PDR without previous PRP therapy were studied. Blood samples were obtained before and 3 months after the last PRP session. Baseline （prelaser） plasma levels of VEGF, ET-1 and NO were compared with their levels in 30 healthy age- and sex- matched controls and also with plasma levels 3 months post-PRP. RESULTS： Patients with PDR had significantly raised plasma VEGF （375 ± 89ng/L）, ET-1 （20 ± 5ng/L） and NO （135 ± 531μmol/L） when compared with healthy control group （P〈 0.01）. After PRP, there was a significant reduction in plasma VEGF （179±66ng/L）, ET-1 （11±5ng/L） and NO （91±49μmol/L） levels at 3 months＇ follow-up but still significantly higher than healthy controls. CONCLUSION： Patients with PDR demonstrate elevated VEGF, ET-1 and NO, which decreased after successful laser treatment.
出处
《国际眼科杂志》
CAS
2009年第10期1843-1846,共4页
International Eye Science
